NCT04179864 2026-03-10
CELLO-1
Ipsen
Phase 1/2 Terminated
Clinical Trials
11 trialsNCT05551117 2026-02-09
Tamarack
MacroGenics
Phase 2 Terminated
NCT01995058 2026-01-08
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
Exelixis
Phase 2 Terminated
NCT02711137 2025-10-21
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Incyte Corporation
Phase 1/2 Terminated
NCT04631601 2025-10-07
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Amgen
Phase 1/2 Terminated
NCT04291664 2024-10-17
PK and Dose Escalation and Expansion Study of DST-2970
DisperSol Technologies, LLC
Phase 1 Terminated
NCT05084859 2024-08-09
A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors
Biosplice Therapeutics, Inc.
Phase 1 Terminated
NCT04726332 2024-05-14
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
Exelixis
Phase 1 Terminated
NCT04677855 2024-04-10
Study of PCUR-101 in Combination With ADT in Patients With mCRPC
Pellficure Pharmaceuticals, Inc
Phase 1 Terminated
NCT04844749 2024-02-05
VERACITY
Veru Inc.
Phase 3 Terminated
NCT03150056 2022-08-10
Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer
GlaxoSmithKline
Phase 1 Terminated